Biomarkers and their use in cervical cancer chemoprevention

Critical Reviews in Oncology/Hematology

Volumn 46, Issue 3, 2003, Pages 261-273

  Vlastos, Anne Thérèse ^a   Schottenfeld, David ^b   Follen, Michele ^c,d  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Carcinoma in situ; Cervical cancer; Cervical intraepithelial neoplasia; Chemoprevention; Human papillomavirus; Surrogate end point biomarkers

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BETA TOCOPHEROL; BIOLOGICAL MARKER; EFLORNITHINE; FENRETINIDE; FOLIC ACID; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POLYAMINE; RETINOIC ACID; RETINOID; RETINOL; RETINOL ACETATE; TRACE ELEMENT; TUMOR MARKER;

CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; COHORT ANALYSIS; COLPOSCOPY; DIET; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE MARKER; DRUG TOLERABILITY; DRUG TOXICITY; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOBIOLOGY; INVASIVE CARCINOMA; NONHUMAN; PATIENT SELECTION; POLYAMINE SYNTHESIS; PRECANCER; REMISSION; REVIEW; SIDE EFFECT; SMOKING CESSATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL BURNING; VAGINAL IRRITATION; VAGINAL PRURITUS; WART VIRUS;

EID: 0038182165     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(02)00107-5     Document Type: Review

References (90)

1. Daly M. The chemoprevention of cancer: directions for the future. Cancer Epidemiol. Biomarkers Prev. 2:1993;509-512.
2. Kelloff G., Malone W., Boone C., Steele V., Doody L. Intermediate biomarkers of precancer and their application in chemoprevention. J. Cell Biochem. Suppl. 16G:1992;15-21.
3. Kelloff G., Johnson J., Crowell J., Boone C., DeGeorge J., Steele V., et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol. Biomarkers Prev. 4:1995;1-10.
4. Boone C., Kelloff G., Steele V. Natural history of intraepithelial neoplasia in humans with implications for cancer chemopreventive strategy. Cancer Res. 52:1992;1651-1659.
5. Kelloff G., Malone W., Boone C., Sigman C., Fay J. Progress in applied chemopreventive research. Semin. Oncol. 17:1990;438-455.
6. Kelloff G., Boone C., Malone W., Steele V. Chemoprevention clinical trials. Mutat. Res. 267:1992;291-295.
7. Kelloff G., Boone C., Crowell J., Steele V., Lubet R., Doody L. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J. Cell Biochem. Suppl. 19:1994;1-9.
8. Mitchell M., Hittelman W., Hong W., Lotan R., Schottenfeld D. The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. Cancer Epidemiol. Biomarkers Prev. 3:1994;619-626.
9. Mitchell M., Hittelman W., Lotan R., Nishioka K., Tortolero-Luna G., Richards-Kortum R., et al. Chemoprevention trials in the cervix: Design, feasibility, and recruitment. J. Cell Biochem. Suppl. 23:1995;104-112.
10. Goodman G. The clinical evaluation of cancer chemoprevention agents: Defining and contrasting phase I, II, and III objectives. Cancer Res. 92:(9 Suppl):1992;2752s-2757s.
11. Muñoz N., Bosch F. Cervical cancer and human papillomavirus: Epidemiological evidence and perspectives for prevention. Salud Pública de México. 39:(4):1997;274-282.
12. Onon T., Kitchener H. The use of vaccines in treating cervical cancer: present status and future prospects. Int. J. Gynecol. Cancer. 9:1999;265-278.
13. Hildesheim A. Human papillomavirus variants: implications for natural history studies and vaccine development efforts. J. Natl. Cancer Inst. 89:1997;752-753.
14. Lowy D., Schiller J. Papillomaviruses: prophylactic vaccine prospects. Biochim. Biophys. Acta. 1423:1998;M1-M8.
15. Galloway D. Is vaccination against human papillomavirus a possibility? Lancet. 351:(Suppl III):1998;22-24.
16. Murakami M., Gurski K., Steller M. Human papillomavirus vaccines for cervical cancer. J. Immunother. 22:1999;212-218.
17. Armstrong B., Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int. J. Cancer. 15:1975;617-631.
18. Willett W., MacMahon B. Diet and cancer: an overview - part I. N. Engl. J. Med. 310:1984;633-637.
19. Willett W., MacMahon B. Diet and cancer: an overview - part II. N. Engl. J. Med. 310:1984;697-703.
20. Willett W. Epidemiologic studies of diet and cancer. Med. Oncol. Tumor Pharmacother. 7:1990;93-97.
21. Mitchell M., Hittelman W., Lotan R., Nishioka K., Tortolero-Luna G., Richards-Kortum R., et al. Chemoprevention trials and surrogate end point biomarkers in the cervix. Cancer. 76:(10 Suppl):1995;1956-1977.
22. Block G. A review of validations of dietary assessment methods. Am. J. Epidemiol. 115:1982;492-505.
23. Lyon J., Gardner J., West D., Mahoney A. Methodological issues in epidemiological studies of diet and cancer. Cancer Res. Suppl. 43:1983;2392-2396.
24. Willett W. Nutritional epidemiology. 1990;Oxford University Press, Oxford.
25. Lee-Han H., McGuire V., Boyd N. A review of the methods used by studies of dietary measurement. J. Clin. Epidemiol. 42:1989;269-279.
26. Borrelli R. Collection of food intake data: a reappraisal of criteria for judging the methods. Br. J. Nutr. 63:1990;411-417.
27. Willett W. Nutritional epidemiology: Issues and challenges. Int. J. Epidemiol. 1987;312-317.
28. Kantesky P., Gammon M., Mandelblatt J.Z.Z., Ramsey E., Dnistrian A., et al. Dietary intake and blood levels of lycopene: association with cervical dysplasia among non-hispanic, black women. Nutr. Cancer. 31:1998;31-40.
29. Wideroff L., Potischman N., Glass A., Greer C., Manos M., Scott D., et al. A nested case-control study of dietary factors and the risk of incident cytological abnormalities of the cervix. Nutr. Cancer. 30:1998;130-136.
30. Peng Y., Peng Y., Childers J., Hatch K., Roe D., Lin Y., et al. Concentrations of carotenoids, tocopherols, and retinol in paired plasma and cervical tissue of patients with cervical cancer, precancer, and noncancerous diseases. Cancer Epidemiol. Biomarkers Prev. 7:1998;347-350.
31. Gamboa-Pinto A., Rock C., Ferruzzi M., Schowinsky A., Schwartz S. Cervical tissue and plasma concentrations of alpha-carotene and beta-carotene in women are correlated. J. Nutr. 128:1998;1933-1936.
32. Nagata C., Shimizu H., Higashiiwai H., Sugahara N., Morita N., Komatsu S., et al. Serum retinol level and risk of subsequent cervical cancer in cases with cervical dysplasia. Cancer Invest. 17:1999;253-258.
33. Potischman N., Hoover R., Brinton L., Swanson C., Herrero R., Tenorio F., et al. The relations between cervical cancer and serological markers of nutritional status. Nutr. Cancer. 21:1994;193-201.
34. Wylie-Rosett J., Romney S., Slagle N., Wassertheil-Smoller S., Miller G., Palan P., et al. Influence of vitamin A on cervical dysplasia and carcinoma in situ. Nutr. Cancer. 6:1984;49-57.
35. Ziegler R., Jones C., Brinton L., Norman S., Mallin K., Levine R., et al. Diet and the risk of in situ cervical cancer among white women in the United States. Cancer Causes Control. 2:1991;17-29.
36. Ziegler R., Brinton L., Hamman R., Lehman H., Levine R., Mallin K., et al. Diet and the risk of invasive cervical cancer among white women in the United States. Am. J. Epidemiol. 132:1990;432-445.
37. Basu J., Palan P., Vermund S., Goldberg G., Burk R., Romney S. Plasma ascorbic acid and β-carotene levels in women evaluated for HPV infection, smoking and cervix dysplasia. Cancer Detect. Prev. 15:1991;165-170.
38. Harris R., Forman D., Doll R., Vessey M., Wald N. Cancer of the cervix uteri and vitamin A. Br. J. Cancer. 53:1986;653-659.
39. Brock K., Berry G., Mock P., MacLennan R., Truswell A., Brinton L. Nutrients in diet and plasma and risk of in situ cervical cancer. J. Natl. Cancer Inst. 80:1988;580-585.
40. Cuzick J., De Stavola B., Russell M., Thomas B. Vitamin A, vitamin E and the risk of cervical intraepithelial neoplasia. Br. J. Cancer. 62:1990;651-652.
41. Batieha A., Armenian H., Norkus E., Morris J., Spate V., Comstock G. Serum micronutrients and the subsequent risk of cervical cancer in a population-based nested case-control study. Cancer Epidemiol. Biomarkers Prev. 2:1993;335-339.
42. Palan P., Mikhail M., Basu J., Romney S. Plasma levels of antioxidant β-carotene and a-tocopherol in uterine cervix dysplasias and cancer. Nutr. Cancer. 15:1991;13-20.
43. VanEenwyk J., Davis F., Bowen P. Dietary and serum carotenoids and cervical intraepithelial neoplasia. Int. J. Cancer. 48:1991;34-38.
44. La Vecchia C., Decarli A., Fasoli M., Parazzini F., Franceschi S., Gentile A., et al. Dietary vitamin A and the risk of intraepithelial and invasive cervical neoplasia. Gynecol. Oncol. 30:1988;187-195.
45. Herrero R., Potischman N., Brinton L., Reeves W., Brenes M., Tenorio F., et al. A case-control study of nutrient status and invasive cervical cancer: I. Dietary indicators. Am. J. Epidemiol. 134:1991;1335-1345.
46. Potischman N., Herrero R., Brinton L., Reeves W., Stacewicz-Sapuntzakis M., Jones C., et al. A case-control study of nutrient status and invasive cervical cancer. II. Serologic indicators. Am. J. Epidemiol. 134:1991;1347-1355.
47. Verreault R., Chu J., Mandelson M., Shy K. A case-control study of diet and invasive cervical cancer. Int. J. Cancer. 43:1989;1050-1054.
48. Romney S., Duttagupta C., Basu J., Palan P., Karp S., Slagle N., et al. Plasma vitamin C and uterine cervical dysplasia. Am. J. Obstet. Gynecol. 151:1985;976-980.
49. Wassertheil-Smoller S., Romney S., Wylie-Rosett J., Slagle S., Miller G., Lucido D., et al. Dietary vitamin C and uterine cervical dysplasia. Am. J. Epidemiol. 114:1990;714-724.
50. Butterworth C.J., Hatch K., Macaluso M., Cole P., Sauberlich H., Soong S., et al. Folate deficiency and cervical dysplasia. JAMA. 267:1992;528-533.
51. Romney S., Dwyer A., Slagle S., Duttagupta C., Palan P., Basu J., et al. Chemoprevention of cervix cancer: phase I-II. A feasibility study involving the topical vaginal administration of retinyl acetate gel. Gynecol. Oncol. 20:1985;109-119.
52. Surwit E., Graham V., Droegemueller W., Alberts D., Chvapil M., Dorr R., et al. Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. Am. J. Obstet. Gynecol. 143:1982;821-823.
53. Meyskens F. Jr., Graham V., Chvapil M., Dorr R., Alberts D., Surwit E. A phase I trial of β-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. J. Natl. Cancer Inst. 71:1983;921-925.
54. Weiner S., Surwit E., Graham V., Jr M.F. A phase I trial of topically applied trans-retinoic acid in cervical dysplasia-clinical efficacy. Invest. New Drugs. 4:1986;241-244.
55. Meyskens F. Jr, Surwit E., Moon T., Childers J., Davis J., Dorr R., et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial. J. Natl. Cancer Inst. 86:1994;539-543.
56. Follen M., Atkinson E., Schottenfeld D., Malpica A., West L., Lippman S., et al. A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin. Cancer Res. 7:2001;3356-3365.
57. Current Clinical Trials Oncology. National Cancer Institute PDQ. Volume 7, Number 1 (January-February 2000) (protocol 13869). 2000.
58. Current Clinical Trials Oncology. National Cancer Institute PDQ. Volume 7, Number 2 (March-April 2000) (protocol awaiting assignment). 2000.
59. Current Clinical Trials Oncology. National Cancer Institute PDQ. Volume 7, Number 2 (March-April 2000) (protocol awaiting assignment). 2000.
60. Romney S., Basu J., Vermund S., Palan P., Duttagupta C. Plasma reduced and total ascorbic acid in human uterine cervix dysplasias and cancer. Ann. N.Y. Acad. Sci. 498:1987;132-143.
61. Butterworth C., Hatch K., Gore H., Mueller H., Krumdieck C. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. Am. J. Clin. Nutr. 35:1982;73-82.
62. Butterworth C., Hatch K., Soong S., Cole P., Tamura T., Sauberlich H. Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. Am. J. Obstet. Gynecol. 166:1992;803-809.
63. Childers J., Chu J., Voigt L., Feigl P., Tamimio H., Franklin E., et al. Chemoprevention of cervical cancer with folic acid: a phase II Southwest Oncology Group Intergroup Study. Cancer Epidemiol. Biomarkers Prev. 4:1995;155-159.
64. Manetta A., Schubbert T., Chapman J., Schell M., Peng Y., Liao S., et al. b-Carotene treatment of cervical intraepithelial neoplasia: A Phase II study. Cancer Epidemiol. Biomarkers Prev. 5:1996;929-932.
65. Romney S., Ho G., Palan P., Basu J., Kadish A., Klein S., et al. Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol. Oncol. 65:1997;483-492.
66. Keefe K. Abstract 144. Twenty-ninth Annual Meeting of the Society of Gynecologic Oncologists; 1998; Walt Disney World Dolphin Resort, February 7-11; 1998. p. 118.
67. Mitchell M., Tortolero-Luna G., Lee J., Hittelman W., Lotan R., Wharton J., et al. Phase I dose de-escalation trial of a-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin. Cancer Res. 4:1998;303-310.
68. Evans T., Kaye S. Retinoids: Present role and future potential. Br. J. Cancer. 80:1999;1-8.
69. Lippman S., Davies P. Retinoids, neoplasia and differentiation therapy. Cancer Chemother Biol. Response Modif. 17:1997;349-362.
70. Delia D., Aiello A., Lombardi L., Pelicci P., Grignani F., Grignani F., et al. N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res. 53:1993;6036-6041.
71. Bartsch D., Boye B., Baust C., zur Hausen H., Schwarz E. Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO J. 11:1992;2283-2291.
72. Batova A., Danielpour D., Pirisi L., Creek K. Retinoic acid induces secretion of latent transforming growth factor β1 and β2 in normal and human papillomavirus type 16-immortalized human keratinocytes. Cell Growth Differ. 3:1992;763-772.
73. Woodworth C., Notario V., DiPaolo J. Transforming growth factors β1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells. J. Virol. 64:1990;4767-4775.
74. Pietrantoni M., Taylor D., Gercel-Taylor C., Bosscher J., Doering D., Gall S. The regulation of HPV oncogene expression by folic acid in cultured human cervical cells. J. Soc. Gynecol. Invest. 2:1995;228.
75. Sporn M., Roberts A. Cervical dysplasia regression induced by all-trans-retinoic acid. J. Natl. Cancer Inst. 86:1994;476-477.
76. M. Ruffin, J. Bailey, D. Underwood, M. Beniasz, L. Gregoire, J. C, et al., The potential use of HPV copy number and E6/E7 expression as biomarkers in cervical dysplasia [abstract 2850]. Proc. Am. Assoc. Cancer Res: 40 (1999).
77. Ho G., Burk R., Klein S., Kadish A., Chang C., Palan P., et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 87:1995;1365-1371.
78. Comerci J., Runowicz C., Fields A., Romney S., Palan P., Kadish A., et al. Induction of transforming growth factor β-1 in cervical intraepithelial neoplasia in vivo after treatment with β-carotene. Clin. Cancer Res. 3:1997;157-160.
79. Current Clinical Trials Oncology. National Cancer Institute PDQ. vol. 1, Number 2 (March-April 1994) (protocol 09088) 1994.
80. Brewer C., Wilczynski S., Kurosaki T., Daood R., Berman M. Colposcopic regression patterns in high-grade cervical intraepithelial neoplasia. Obstet. Gynecol. 90:1997;617-621.
81. Auvinen M., Paasinen A., Andersson L., Hölttä E. Ornithine decarboxylase activity is critical for cell transformation. Nature. 360:1992;355-358.
82. Nishioka K., Melgarejo A., Lyon R., Mitchell M. Polyamines as biomarkers of cervical intraepithelial neoplasia. J. Cell Biochem. (Suppl). 23:1995;87-95.
83. Verma A., Boutwell R. Inhibition of carcinogenesis by inhibitors of putrescine biosynthesis. McCann P., Pegg A., Sjoerdsma A. Inhibition of polyamine metabolism, biological significance and basis for new therapies. 1987;249-258 Academic Press, Orlando, Florida.
84. Tempero M., Nishioka K., Knott K., Zetterman R. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. Cancer Res. 49:1989;5793-5797.
85. Boiko I., Mitchell M., Pandey D., White R., Hu W., Malpica A., et al. DNA image cytometric measurement as a surrogate end point biomarker in a Phase I trial of a-difluoromethylornithine for cervical intraepithelial neoplasia. Cancer Epidemiol. Biomarkers Prev. 6:1997;849-855.
86. Bacus J., Boone C., Bacus J., Follen M., Kelloff G., Kagan V., et al. Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials. Cancer Epidemiol. Biomarkers Prev. 8:1999;1087-1094.
87. Hu W., Mitchell M., Boiko I., Linares A., Kim H., Malpica A., et al. Progressive dysregulation of proliferation during cervical carcinogenesis as measured by MPM-2 antibody staining. Cancer Epidemiol. Biomarkers Prev. 6:1997;711-718.
88. Hu W., Boiko I., Mitchell M., Hittelman W. Sequential dysregulation of proliferation during cervical carcinogenesis. Proc. Am. Assoc. Cancer Res. A3500:1995;588.
89. Boiko I., Mitchell M., Hu W., Pandey D., Mathevet P., Malpica A., et al. Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an a-difluoromethylornithine chemoprevention trial. Clin. Cancer Res. 4:1998;1383-1391.
90. Mitchell M., Tortolero-Luna G., Lee J., Hittelman W., Lotan R., Wharton J., et al. Polyamine measurements in the uterine cervix. J. Cell Biochem. Suppl. 28/29:1997;125-132.